Interim / Quarterly Report • Aug 22, 2023
Interim / Quarterly Report
Open in ViewerOpens in native device viewer
•
•
•
•
•
•
•
| 2023 | 2022 | 2023 | 2022 | 2022 | |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec | |
| Net revenue, MSEK | 5.9 | 4.7 | 12.7 | 11.8 | 22.6 |
| Result after tax, MSEK | -79.5 | -33.2 | -154.4 | -62.1 | -193.8 |
| Cash flow, MSEK | -64.8 | 124.3 | 51.0 | 86.5 | -19.5 |
| Cash, MSEK | 179.2 | 233.2 | 179.2 | 233.2 | 127.7 |
| Equity ratio, % | 90% | 96% | 90% | 96% | 90% |
| Earnings per share, SEK | -0.3 | -0.2 | -0.6 | -0.3 | -1.0 |
| Earnings per share after dilution, SEK | -0.3 | -0.2 | -0.6 | -0.3 | -1.0 |
| Average number of employees | 26 | 13 | 23 | 13 | 15 |
Egetis Therapeutics is an innovative and integrated pharmaceutical company, focusing on projects in latestage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
The Company's lead drug candidate Emcitate is under development for the treatment of patients with monocarboxylate transporter 8 (MCT8) deficiency, a highly debilitating rare disease with no available treatment. In previous studies (Triac Trial I and a longterm real-life study) Emcitate has shown highly significant and clinically relevant results on serum thyroid hormone T3 levels and secondary clinical endpoints. As a result of regulatory interaction Egetis intends to submit a marketing authorisation application (MAA) for Emcitate to the European Medicines Agency (EMA) on October 9, 2023, based on existing clinical data.
After a dialogue with the FDA, Egetis is conducting a small randomized, placebo-controlled pivotal study in 16 patients to verify the results on T3 levels seen in previous clinical trials and publications. Egetis intends to submit a new drug application (NDA) in the US for Emcitate in mid 2024 under the Fast-Track Designation granted by FDA.
Emcitate holds Orphan Drug Designation (ODD) for MCT8 deficiency and resistance to thyroid hormone type beta (RTH-beta) in the US and the EU. MCT8 deficiency and RTH-beta are two distinct indications, with no overlap in patient populations. Emcitate has been granted Rare Pediatric Disease Designation (RPDD) which gives Egetis the opportunity to receive a Priority Review Voucher (PRV) in the US, after approval. This voucher can be transferred or sold to another sponsor.
The drug candidate Aladote is a first in class drug candidate developed to reduce the risk of acute liver injury associated with paracetamol (acetaminophen) overdose. A proof of principle study has been successfully completed and the design of the upcoming pivotal Phase lib/III study with the purpose of applying for market approval in the US and Europe for Aladote has been finalized after completed interactions with FDA, EMA and MHRA and study start is planned after Emcitate submissions have been completed. Aladote has been granted ODD in the US and in the EU.
Egetis Therapeutics (STO: EGTX) is listed on the Nasdag Stockholm main market. For more information, see www.egetis.com
Announced site activation in the pivotal ReTRIACt trial for Emcitate and updated timeline for the US NDA submission
Announced first patient included and second site activated in the ReTRIACt trial, which is pivotal for the US NDA submission
Emcitate is Egetis' lead drug candidate in clinical development. It addresses monocarboxylate transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley Syndrome (AHDS), a rare genetic disease that affects 1 in 70,000 men with high unmet medical need with no available treatment.
Thyroid hormones are crucial for the development and metabolic state of virtually all tissues. Thyroid hormone transport across the plasma membrane is required for the hormones' metabolism and intracellular action and is facilitated by thyroid hormone transporters, including MCT8. Mutations in the gene for MCT8 cause MCT8 deficiency. The gene is located on the X chromosome and therefore mainly affects men, as men only have one X chromosome.
The resulting dysfunction of MCT8 leads to impaired transport of thyroid hormone into certain cells and across the blood-brain-barrier and disruption of normal thyroid hormone regulation. Patients with MCT8 deficiency therefore have low concentrations of thyroid hormone in the central nervous system, which signals that the body should produce more thyroid hormone. This leads to increased levels of active thyroid hormone T3 in peripheral tissues, also called thyrotoxicosis. This leads to a complex pattern of symptoms with neurological developmental delay and intellectual disability, accompanied by severely elevated circulating thyroid hormone concentrations which are toxic for tissues including the heart, muscle, liver and kidney and results in symptoms such as failure to thrive, cardiovascular stress, insomnia and muscle wasting.
Most patients will never develop the ability to walk or even sit independently. At present there is no approved therapy available for the treatment of MCT8 deficiency.
Emcitate was granted Orphan Drug Designation in the EU in 2017 and the US in 2019. Emcitate received US Rare Paediatric Disease Designation (RPDD) in 2020. Upon approval of the NDA, sponsors holding a RPDD and meeting the criteria specified can apply to receive a Priority Review Voucher (PRV). A PRV provides accelerated FDA review of a subsequent new drug application for any drug candidate, in any indication, shortening time to market in the US. The voucher may also be sold or transferred to another sponsor. During the last few years PRVs have been sold for around \$100 million.
A Phase IIb clinical trial (Triac Trial I) in MCT8 deficiency has been completed which showed significant and clinically relevant treatment effects on key aspects of the disease. In October 2021, strong data from long-term treatment in patients with MCT8 deficiency up to 6 years, with Emcitate was published in the Journal of Clinical Endocrinology & Metabolism. The data comes from an investigator-initiated real-life cohort study at 33 sites conducted by the Erasmus Medical Center, Rotterdam, The Netherlands, where the efficacy and safety of Emcitate was investigated in 67 patients with MCT8 deficiency.
Based on the new long-term data in 2021, Egetis had further interactions with the regulatory agencies in the US and Europe. In December 2021, the EMA concluded that the clinical data from the Triac Trial I, together with the published data from long-term treatment, will suffice for a regulatory submission of a Marketing
Authorisation Application (MAA) to the EMA for the treatment of MCT8 deficiency. Egetis plans to submit the MAA on October 9, 2023.
FDA acknowledges that a treatment effect on T3 levels and the manifestations of chronic thyrotoxicosis in MCT8-deficiency could provide a basis for marketing approval also in the US. Egetis has agreed with the FDA to perform a small, randomized study in 16 patients for up to 30 days to verify the T3 results, seen in previous clinical trials and publications. The design of this study (ReTRIACt) is available on clinicaltrials.gov under the code NCT055793. It is well established that the T3 levels in untreated MCT8 patients are significantly elevated, and we have previously shown that Emcitate is able to normalize these levels rapidly and durably. Egetis is targeting an US NDA submission for Emcitate in mid 2024 under the Fast Track Designation granted by the FDA.
A Phase IIb/III early intervention study (Triac Trial II) was initiated in 2020. This study is an international, open label, multi-center study in boys younger than 30 months with MCT8 deficiency, conducted in both Europe and North America. The design of the Triac Trial II study is available on clinicaltrials.gov under the
code NCT02396459. The recruitment target was reached in April 2022, with 22 patients included in the study. Results from the Triac Trial II are expected in mid 2024.
Emcitate is already supplied to over 180 patients on a named patient or compassionate use basis, following individual regulatory approvals from national regulatory agencies in over 25 countries. Compassionate use and named patient programs are mechanisms to allow early access to a medicine prior to regulatory marketing approval, granted to pharmaceuticals under development for conditions with high unmet medical needs and where no available treatment alternatives exist.
Emcitate has been granted orphan drug designation (ODD) for RTH- $\beta$ in the USA and the EU. RTH- $\beta$ is an additional indication, without overlap in patient populations, to the previously obtained ODD for MCT8 deficiency. The ODD for RTH-β is a direct result of Egetis' work to extend the indications for the Emcitate program to related but distinct conditions.
• Announced that in-house development of Aladote will be parked, until Emcitate submissions have been completed
Aladote is a first-in-class drug candidate with the potential to reduce the risk of acute liver failure associated with paracetamol/acetaminophen poisoning. Aladote has shown a beneficial effect in relevant preclinical models, even in the timewindow when N-acetylcysteine (NAC) treatment no longer is effective (>8 hours). A proof of principle study in patients with paracetamol poisoning to prevent acute liver injury has been successfully completed. The study results established the safety and tolerability of the combination of Aladote and NAC. Further, the results indicate that Aladote may reduce acute liver injury in this patient population.
Aladote has been granted Orphan Drug Designation (ODD) in the US and EU.
Paracetamol/acetaminophen is the most used drug in the world for the treatment of fever and pain, but also one of the most overdosed drugs intentionally or unintentionally. Paracetamol overdose is one of the most common methods in
suicide attempts. When excessive amounts of paracetamol are metabolized in the liver, the harmful metabolite N-acetyl-p-benzoquinone imine (NAPQI) is formed, which can cause acute liver failure. The current standard of care for paracetamol poisoning, NAC, is effective if the patient receives medical care within eight hours of ingestion.
A pivotal Phase IIb/III study, Albatross, has been parked until Emcitate submissions have been completed. This study will be targeting patients with increased risk of liver injury, who arrive late at hospital, more than eight hours after a paracetamol overdose, for which current standard of care, NAC, is substantially less effective. The total planned number of patients is around 250, who will be enrolled in the US, UK and in at least one EU country. The study consists of two parts with an interim analysis which includes a futility analysis and dose selection where the most effective dose will be continued.
Revenue amounted to MSEK 5,9 (4,7) during the quarter and MSEK 12,7 (11,8) for the period. The Revenue consisted of "Named Patient Use" Emcitate sales of MSEK 5,9 (4,7) during the quarter and MSEK 12,7 (11,2) during the period. Revenue in the comparative period previous year included forwarding of expenses related to PledOx to Solasia Pharma K.K. (Solasia) with an amount of MSEK 0,5.
Operating expenses amounted to MSEK-86,2 (-40,0) during the quarter and MSEK-167,9 (-76,2) during the period. The project expenses amounted to MSEK-41,5 (-22,6) during the quarter and MSEK-89,4 (-42,3) during the period. The project expenses consisted of expenses due to Emcitate of MSEK-41,0 (-22,4) and Aladote of MSEK-0,6 (-0,1), during the quarter and MSEK-88,1 (-39,5) for Emcitate and MSEK-1,3 (-2,0) for Aladote during the period.
Employee costs amounted to MSEK-15,8 (-10,2) during the quarter and MSEK-31,2 (-18,7) during the period. The cost increase is due to the increase of number of employees ahead of the anticipated commercial launch of Emcitate. The costs also include participants' earnings in the employee stock option plans of MSEK 1,4 (-1,1) for the quarter and MSEK-1,1 (-2,1) for the period. Costs for the employee stock option plans will continue to vary with the share price development and do not impact cash flow.
Other external costs amounted to MSEK-25.5 (-5.0) during the quarter and MSEK-40,4 (-10,3) during the period. The increase is mainly due to higher consultancy costs related to Egetis' investments ahead of the planned commercial launch of Emcitate. These include among others, work related to the upcoming submissions with major healthcare agencies around the world. Depreciation amounted to MSEK-0,9 (-0,7) for the quarter and MSEK-1,8 (-1,3) during the period. The depreciation during the period derives from amortization of licences with MSEK-0,5 (-0,5), depreciation of right-of-use assets with MSEK-1,2 (-0,8) and depreciation of inventories with MSEK-0,1 (-0,0). Other operating expenses amounted to MSEK-1,1 (-) for the quarter and MSEK-1,5 (-) for the period and consists of exchange rate differences from operating income and operating expenses.
Operating results amounted to MSEK-80,3 (-35,0) for the quarter and MSEK-155,2 (-64,4) for the period. Net financial items amounted to MSEK 0,8 $(1,7)$ for the quarter and MSEK 0,8 (2,3) for the period. Results from net financial items are related to unrealized revaluation of company's FX-accounts. Results after financial items amounted to MSEK-79,5 (-33,2) for the quarter and MSEK-154,4 (-62,1) for the period. Results per share before and after dilution amounted to SEK -0.3 (-0.2) for the quarter and SEK -0.6 (-0.3) for the period both before and after dilution.
Cash as of June 30, 2023, amounted to MSEK 179,2 $(233,2)$ .
Cash flow from operating activities amounted to MSEK -64,2 (-35,3) for the quarter and -143,6 (-68,4) for the period. Total Cash flow amounted to MSEK-64,8 (124,3) for the quarter and MSEK 51,0 (86,5) for the period. Cash flow from operating activities is driven by costs related to the ongoing clinical studies and the preparations ahead of the anticipated commercial launch of Emcitate.
Cash flow from investment activities amounted to MSEK-0,0 (-1,7) during the period. The figures in the comparative period previous year included payment
of deferred purchase price for the acquisition of Rare Thyroid Therapeutics International AB (RTTI AB). Cash flow from financing activities amounted to MSEK-0,6 (159,5) for the quarter and MSEK 194,7 (156,6) for the period and derives mainly from the directed shares issue of 35,000,000 shares at SEK 6.00, that was completed during January 2023.
As of June 30, 2023, equity amounted to MSEK 550,9 (635,0). Shareholders' equity per average number of shares amounted to SEK 2.3 (3.4), at the end of the period. The company's equity ratio was 90 (96) %.
As of June 30, 2023, non-current liabilities amounted to MSEK 5,8 (2,6). These consist mainly of liabilities that derive from right of use liabilities according to IFRS 16 of MSEK 3,3 (1,9) and provisions for social security contributions relating to stock option plans of MSEK 2,5 (0,7). Current liabilities amount to MSEK 52,1 (23,6) of which other liabilities and accrued expenses amount to MSEK 30,9 (18,7) and accounts payable amount to MSEK 21,2 (4,9).
As of June 30, 2023, non-current intangible assets amounted to MSEK 415,1 (414,1). No significant investments were allocated to tangible assets during the period.
The number of shares as of June 30, 2023, were 249,589,128. The number of shares has increased with 35,000,00 shares as a result of a directed new share issue during January. The number of shareholders were 7,488 as of June 30, 2023. The 10 largest shareholders hold 62.0 % of outstanding shares. Egetis Therapeutics shares are listed on Nasdaq Stockholm's main market.
For information about current and previous employee stock option programs please see note 6.
Number of employees as of June 30, 2023, were 28 (15) persons, 17 women and 11 men (8 women and 7 men).
The parent company's Revenue for the quarter amounted to MSEK - (-) and MSEK - (0,5) for the period. Revenue in the prior period were due to forwarding of expenses related to PledOx to Solasia. Other income for the quarter amounted to MSEK 22,8 (10,1) and MSEK 42,3 (16,6) for the period. Other income for the period consisted of MSEK 19,9 (12,3) management fees invoiced to the subsidiaries RTTI AB and Egetis US Inc., MSEK 22,3 (4,3) for forwarding of expenses to RTTI AB and MSEK 0,1 (0,1) as exchange rate gains. Operating expenses amounted to MSEK-15,7 (-21,0) for the quarter and MSEK-32,0 (-39,0) for the period. The project expenses amounted to MSEK-12,3 (-5,6) for the quarter and MSEK-23,6 (-9,5) during the period. The parent company's results amounted to MSEK -94,8 (-34,2) for the quarter and MSEK-131,1 (-44,4) for the period.
Financial non-current assets amount to MSEK 434,1 (433,5) and other long-term liabilities amount to MSEK $2,5(0,7)$ .
| MSEK | 2023 | 2022 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec | |
| Revenue Revenue |
5.9 | 4.7 | 12.7 | 11.8 | 22.6 |
| Other operating income | 0.0 | 0.4 | 0.0 | 0.1 | - |
| Operating expenses | 5.9 | 5.0 | 12.7 | 11.8 | 22.6 |
| Costs of sales of goods | -1.3 | -1.5 | -3.6 | -3.5 | -6.3 |
| Project costs | -41.5 | -22.6 | -89.4 | -42.3 | -136.3 |
| Other external costs | -25.5 | -5.0 | -40.4 | -10.3 | -22.3 |
| Employee costs | -15.8 | -10.2 | -31.2 | -18.7 | -52.0 |
| Depreciation and impairment | -0.9 | -0.7 | -1.8 | -1.3 | -2.7 |
| Other operating expenses | -1.1 | - | -1.5 | - | -1.1 |
| Sum operating expenses | -86.2 | -40.0 | -167.9 | -76.2 | -220.6 |
| Operating results | -80.3 | -35.0 | -155.2 | -64.4 | -198.1 |
| Financial items | |||||
| Interest income and similar items | 0.8 | 1.8 | 0.9 | 2.4 | 5.0 |
| Interest expense and similar items | -0.0 | -0.0 | -0.1 | -0.1 | -0.7 |
| Sum financial items | 0.8 | 1.7 | 0.8 | 2.3 | 4.3 |
| Results after financial net | -79.5 | -33.2 | -154.4 | -62.1 | -193.8 |
| Tax | - | - | - | - | - |
| Net loss for the period | -79.5 | -33.2 | -154.4 | -62.1 | -193.8 |
| Net earnings and comprehensive income is entirely | |||||
| attributable to parent company shareholders | |||||
| Share Data | |||||
| Number of shares at the end of period | 249,589,128 | 214,589,128 | 249,589,128 | 214,589,128 | 214,589,128 |
| Average number of shares during period, before dilution | 249,589,128 | 198,292,502 | 244,561,504 | 189,099,479 | 194,238,210 |
| Average number of shares during period, after dilution | 255,537,608 | 198,292,502 | 249,612,356 | 189,099,479 | 194,238,210 |
| Earnings per share before dilution (SEK) | -0.3 | -0.2 | -0.6 | -0.3 | -1.0 |
| Earnings per share after dilution (SEK) | -0.3 | -0.2 | -0.6 | -0.3 | -1.0 |
| Equity per average number of shares | 2.2 | 3.2 | 2.3 | 3.4 | 2.6 |
| Equity per average number of shares after dilution | 2.2 | 3.2 | 2.3 | 3.4 | 2.6 |
| MSEK | 2023 | 2022 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec | |
| Net loss for the period | -79.5 | -33.2 | -154.4 | -62.1 | -193.8 |
| Translation exchange rate differences | 0.2 | - | 0.2 | - | 0.0 |
| Comprehensive income for the period | -79.3 | -33.2 | -154.2 | -62.1 | -193.8 |
| MSEK | 30/06/2023 | 30/06/2022 | 31/12/2022 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Research and development costs | 404.8 | 404.8 | 404.8 |
| Licences | 4.9 | 5.9 | 5.4 |
| Right-of-use assets | 5.4 | 3.3 | 2.6 |
| Equipment | 0.1 | 0.1 | 0.1 |
| Financial non-current assets | 0.8 | 0.8 | 0.8 |
| Total non-current assets | 416.0 | 415.0 | 413.7 |
| Current assets | |||
| Inventories | 0.1 | 0.2 | 0.6 |
| Accounts receivables | 4.2 | 4.2 | 3.8 |
| Other receivables | 6.6 | 3.3 | 6.4 |
| Prepaid expenses and accrued income | 2.6 | 5.1 | 8.9 |
| Cash and bank balance | 179.2 | 233.2 | 127.7 |
| Total current assets | 192.7 | 246.1 | 147.4 |
| Total assets | 608.8 | 661.1 | 561.1 |
| MSEK | 30/06/2023 | 30/06/2022 | 31/12/2022 |
|---|---|---|---|
| Equity | |||
| Share capital | 13.1 | 11.3 | 11.3 |
| Other capital contributions | 1,622.6 | 1,428.4 | 1,428.4 |
| Reserves | 9.1 | 3.1 | 6.1 |
| Accumulated loss including net loss | -1,093.9 | -807.9 | -939.6 |
| Total equity | 550.9 | 635.0 | 506.2 |
| Non-current liabilities | |||
| Other non-current liabilities | 3.3 | 1.9 | 1.1 |
| Provisions | 2.5 | 0.7 | 4.4 |
| Total non-current liabilities | 5.8 | 2.6 | 5.5 |
| Current liabilities | |||
| Accounts payable | 21.2 | 4.9 | 20.0 |
| Other liabilities | 8.1 | 4.3 | 5.7 |
| Accrued expenses and deferred income | 22.8 | 14.4 | 23.7 |
| Total current liabilities | 52.1 | 23.6 | 49.4 |
| Total equity and liabilities | 608.8 | 661.1 | 561.1 |
| MSEK | 2023 | 2022 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec | |
| OPERATING ACTIVITIES | |||||
| Result after financial net | $-79.5$ | $-33.2$ | $-154.4$ | $-62.1$ | $-193.8$ |
| Adjustments for non-cash items | $-0.3$ | 0.3 | 3.3 | 1.4 | 9.4 |
| Tax paid | |||||
| Cash flow from operating activities before changes | $-79.8$ | $-32.9$ | $-151.1$ | $-60.6$ | $-184.4$ |
| in working capital | |||||
| Cash flow from changes in working capital | |||||
| Increase/decrease in operating receivables | 2.1 | $-0.5$ | 6.1 | $-3.9$ | $-10.7$ |
| Increase/decrease in operating liabilities | 13.6 | $-1.8$ | 1.3 | $-3.9$ | 21.6 |
| Cash flow from changes in working capital | 15.6 | $-2.4$ | 7.5 | $-7.8$ | 10.9 |
| Cash flow from operating activities | $-64.2$ | $-35.3$ | $-143.6$ | $-68.4$ | $-173.5$ |
| INVESTING ACTIVITIES | |||||
| Acquisition of subsidiaries, net cash required | $-1.7$ | $-1.7$ | |||
| Investment in financial assets | $-0.0$ | $-0.0$ | 0.0 | ||
| Purchase of property, plant and equipment | $-0.0$ | $\overline{\phantom{a}}$ | $-0.0$ | ||
| Cash flow from investing activities | $-0.0$ | $-0.0$ | $-1.7$ | $-1.7$ | |
| FINANCING ACTIVITIES | |||||
| New share issue | 177.4 | 210.0 | 177,4 | 177.4 | |
| Cost of new share issue | $-12.6$ | $-14.0$ | $-12.6$ | $-12.6$ | |
| Repayment of loans | $-5.0$ | $-7.5$ | $-7.5$ | ||
| Repayment of leases | $-0.6$ | $-0.3$ | $-1.3$ | $-0.7$ | $-1.6$ |
| Cash flow from financing activities | $-0.6$ | 159.5 | 194.7 | 156.6 | 155.7 |
| Cash flow for the period | $-64.8$ | 124.3 | 51.0 | 86.5 | $-19.5$ |
| Balance at beginning of period | 243.5 | 106.8 | 127.7 | 144.0 | 144.0 |
| Change in cash | $-64.8$ | 124.2 | 51.0 | 86.4 | $-19.5$ |
| Exchange rate difference in cash | 0.5 | 2.2 | 0.4 | 2.8 | 3.2 |
| CASH BALANCE AT THE END OF THE PERIOD | 179.2 | 233.2 | 179.2 | 233.2 | 127.7 |
| MSEK | Share capital |
Other capital contributions |
Accumulated loss incl. net results for the period |
Other reserves | Total equity |
|---|---|---|---|---|---|
| Opening balance 01/01/2023 | 11.3 | 1,428.4 | -939.6 | 6.1 | 506.2 |
| Rights issue | 1.8 | 208.2 | - | - | 210.0 |
| Costs, rights issue | - | -14.0 | - | - | -14.0 |
| Comprehensive income for the period | - | - | -154.2 | - | -154.2 |
| Transactions with shareholders | |||||
| Costs due to share-based payments of employee stock option plan |
- | - | - | 2.9 | 2.9 |
| Closing balance 30/06/2023 | 13.1 | 1,622.6 | -1,093.8 | 9.0 | 550.9 |
| Opening balance 01/01/2022 | 8.7 | 1,262.8 | -745.8 | 1.3 | 527.0 |
| Rights issue | 2.6 | 178.1 | - | - | 180.8 |
| Costs, rights issue | - | -12.6 | - | - | -12.6 |
| Comprehensive income for the period | - | - | -193.8 | - | -193.8 |
| Transactions with shareholders | |||||
| Costs due to share-based payments of employee stock option plan |
- | - | - | 4.8 | 4.8 |
| Closing balance 31/12/2022 | 11.3 | 1,428.4 | -939.6 | 6.1 | 506.2 |
| MSEK | 2023 | 2022 | 2022 |
|---|---|---|---|
| Jan-Jun | Jan-Jun | Jan-Dec | |
| Equity | 550.9 | 635.0 | 506.2 |
| Equity ratio % | 90% | 96% | 90% |
| Number of shares at the end of the period | 249,589,128 | 214,589,128 | 214,589,128 |
| Average number of shares during the period | 244,561,504 | 189,099,479 | 194,238,210 |
| Average number of shares during the period after dilution | 249,612,356 | 189,099,479 | 194,238,210 |
| Share Data | |||
| Earnings per share | -0.6 | -0.3 | -1.0 |
| Earnings per share after dilution | -0.6 | -0.3 | -1.0 |
| Cash flow from operating activities | -0.6 | -0.4 | -0.9 |
| Equity per average number of shares | 2.3 | 3.4 | 2.6 |
| Equity per average number of shares after dilution | 2.3 | 3.4 | 2.6 |
| Dividend | - | - | - |
| Average number of employees | 23 | 13 | 15 |
*Effect from dilution is not considered when result is negative.
| MSEK | 2023 | 2022 | 2023 | 2022 | 2022 |
|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec | |
| Revenue | |||||
| Revenue | - | - | - | 0.5 | 0.6 |
| Other operating income | 22.8 | 10.1 | 42.3 | 16.6 | 53.6 |
| 22.8 | 10.1 | 42.3 | 17.2 | 54.2 | |
| Operating expenses | |||||
| Project costs | -12.3 | -5.6 | -23.6 | -9.5 | -42.4 |
| Other external costs | -11.6 | -5.1 | -20.6 | -10.6 | -22.4 |
| Employee costs | -14.3 | -10.2 | -29.7 | -18.7 | -52.0 |
| Depreciation and impairment | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 |
| Other operating expenses | -0.2 | -0.1 | -0.4 | -0.1 | -0.6 |
| Sum operating expenses | -38.5 | -21.0 | -74.4 | -39.0 | -117.4 |
| Operating results | -15.7 | -10.9 | -32.0 | -21.8 | -63.2 |
| Financial items | |||||
| Interest income and similar items | 0.9 | 1.8 | 0.9 | 2.4 | 3.7 |
| Interest expense and similar items | 0.0 | - | 0.0 | - | 0.0 |
| Sum financial items | 0.9 | 1.8 | 0.9 | 2.4 | 3.7 |
| Results after financial net | -14.8 | -9.2 | -31.1 | -19.4 | -59.5 |
| Group contributions | -80.0 | -25.0 | -100.0 | -25.0 | -135.0 |
| Tax | - | - | - | - | - |
| Results after tax | -94.8 | -34.2 | -131.1 | -44.4 | -194.5 |
| MSEK | 30/06/2023 | 30/06/2022 | 31/12/2022 |
|---|---|---|---|
| ASSETS | |||
| Non-current assets | |||
| Equipment | 0.1 | 0.1 | 0.1 |
| Financial non-current assets | 434.1 | 433.5 | 433.8 |
| Total non-current assets | 434.2 | 433.6 | 433.9 |
| Current assets | |||
| Receivables from Group companies | 0.5 | - | 0.1 |
| Other receivables | 0.5 | 0.0 | 0.6 |
| Prepaid expenses and accrued income | 4.4 | 2.6 | 3.8 |
| Cash and bank balance | 161.7 | 220.9 | 120.0 |
| Total current assets | 167.1 | 223.4 | 124.4 |
| Total assets | 601.3 | 657.0 | 558.3 |
| MSEK | 30/06/2023 | 30/06/2022 | 31/12/2022 |
|---|---|---|---|
| Equity | |||
| Restricted Equity | |||
| Share capital | 13.1 | 11.3 | 11.3 |
| Non-restricted equity | |||
| Share premium reserve | 673.5 | 673.8 | 673.8 |
| Reserves | 9.0 | 3.1 | 6.1 |
| Net loss for the period | -131.1 | -44.4 | -194.5 |
| Total equity | 564.5 | 643.8 | 496.7 |
| Non-current liabilities | |||
| Provisions | 2.5 | 0.7 | 4.4 |
| Total non-current liabilities | 2.5 | 0.7 | 4.4 |
| Current liabilities | |||
| Liabilities to group company | 14.1 | 1.6 | 33.1 |
| Accounts payable | 5.2 | 2.4 | 7.8 |
| Other liabilities | 5.6 | 2.5 | 3.9 |
| Accrued expenses and deferred income | 9.4 | 6.1 | 12.4 |
| Total current liabilities | 34.3 | 12.5 | 57.2 |
| Total equity and liabilities | 601.3 | 657.0 | 558.3 |
Egetis applies International Financial Reporting Standards (IFRS) as adopted by the EU. This report is prepared in accordance with IAS 34 Interim Financial Reporting and the Annual Accounts Act and should be read together with the Egetis consolidated financial statements for the year ended December 31, 2022. The interim report does not include all disclosures that would otherwise be required in a complete set of financial statements. Applied accounting principles and calculation methods are the same as in the latest annual report for 2022. Some amendments to existing standards became applicable from January 1, 2023, however none of these have a material impact on the consolidated financial statements or accounting policies. The parent company and the Group's accounting currency is SEK. All the numbers in this interim report are, if nothing else is stated, presented in million SEK.
The preparation of interim reports requires certain critical accounting estimates to be made. Furthermore, company management is required to make assessments when applying accounting principles. See the Group's accounting principles in the annual report 2022 regarding more information on estimates and assessments.
The parent company Egetis Therapeutics AB (publ) prepares financial reports in accordance with the Swedish Financial Reporting Board's recommendation RFR 2 Accounting for Legal Entities and the Swedish Annual Accounts Act. The parent company applies the exception from application of IFRS 16 Leases.
All business operations involve risk. Risks may be company specific or due to events in the external environment and may affect a certain industry or market. The group is, among others, exposed to the following operational and financial risks.
Pharmaceutical development, Manufacturing, Regulatory, Commercialization, Competition and Market Acceptance and Intellectual property.
Foreign currency, Need of working capital, General market risk, Credit and Interest rate risks.
A more detailed description of the Group's risk exposure is included in Egetis 2022 Annual Report, Risks and Risk Management section and Note 3. There are no major changes in the Group's risk exposure in 2023 compared with 2022.
Egetis Therapeutics is dependent on the efficient and uninterrupted operation of various IT systems to run its business. A significant breakdown or other disruption in the IT systems (for example as a result of a virus attack or network congestion attacks) can affect the ability to conduct business in general and can lead to delays and increased costs in the Company's research and development work.
There is a risk that the Company, as a result of such as viral pandemics, will not succeed in recruiting participants for its clinical studies, either because participants do not want, or due to restrictions should not, visit hospitals to avoid infection. There is also a risk that new variants of different microorganisms will lead to lockdowns in
Sweden or in other countries, which could mean that the Company or its partners cannot conduct research and development work according to the existing clinical development plan. There is also a risk that caregivers need to allocate resources to meet the effects of different pandemics, which can lead to limited resources to participate in the Company's clinical trials.
Continued and/or escalating tension between Russia and Ukraine led to Russia's full-scale military invasion of Ukraine and current inflationary situation in the society could have a significant negative impact on the global macroeconomic situation and the Swedish economy. It could result in the Company or its partners not being able to conduct R&D efforts according to plan.
A more detailed description of the Group's risk exposure is included in Egetis 2022 Annual Report, Risks and Risk Management section and Note 3. There are no major changes in the Group's risk exposure in 2023 compared with 2022.
Other information in accordance with IAS 34.16A are found on the pages before the income statement and statement of comprehensive income. For information on earnings, cash flow and financial position, see page 9. For events after the period, see page 1.
The Group applies segment reporting with mainly two independent development areas, Emcitate and Aladote. The highest executive decision-maker in the Company allocates the Company's resources between these two R&D projects. Revenue for Emcitate is attributable to the "Named Patient Use" use of the drug candidate.
Revenue and expenses attributable to Emcitate and Aladote are reported below.
| 2023 | 2022 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Apr-Jun | Apr-Jun | ||||||||
| MSEK | Emcitate | Aladote Common* | Sum | MSEK | Emcitate | Aladote Common* | Sum | ||
| Revenue | 5.9 | $\overline{\phantom{a}}$ | $\overline{\phantom{a}}$ | 5.9 | Revenue | 4.7 | $\overline{\phantom{a}}$ | $\sim$ | 4.7 |
| Costs of sales of goods | $-1.3$ | $\overline{\phantom{a}}$ | $-1.3$ | Costs of sales of goods | $-1.5$ | - | $-1.5$ | ||
| Project costs | $-41.0$ | $-0.6$ | $\overline{\phantom{a}}$ | $-41.5$ | Project costs | $-22.4$ | $-0.1$ | $-0.1$ | $-22.6$ |
| Other | $\overline{\phantom{a}}$ | $\sim$ | $-43.3$ | $-43.3$ | Other | $\overline{\phantom{a}}$ | $\overline{\phantom{a}}$ | $-15.5$ | $-15.5$ |
| Operating results | $-36.4$ | $-0.6$ | $-43.3$ | $-80.3$ | Operating results | $-19.3$ | $-1.9$ | $-15.6$ | $-35.0$ |
| Net financial items | 0.8 | Net financial items | 1.7 | ||||||
| Pretax profit | $-79.5$ | Pretax profit | $-33.2$ |
| 2023 | ||||
|---|---|---|---|---|
| Jan-Jun | ||||
| MSEK | Emcitate | Aladote Common* | Sum | |
| Revenue | 12.7 | 12.7 | ||
| Costs of sales of goods | $-3.6$ | $-3.6$ | ||
| Project costs | $-88.1$ | $-1.3$ | $-89.4$ | |
| Other | $-74.9$ | $-74.9$ | ||
| Operating results | $-79.0$ | $-1.3$ | $-74.9$ | $-155.2$ |
| Net financial items | 0.8 | |||
| Pretax profit | $-154.4$ |
| 2022 | ||||
|---|---|---|---|---|
| Jan-Jun | ||||
| MSEK | Emcitate | Aladote | Common | Sum |
| Revenue | 11.2 | ۰ | 0.5 | 11.8 |
| Costs of sales of goods | $-3.5$ | - | $-3.5$ | |
| Project costs | $-39.5$ | $-2.0$ | $-0.9$ | $-42.3$ |
| Other | ۰ | $-30.3$ | $-30.3$ | |
| Operating results | $-31.8$ | $-2.0$ | $-30.7$ | $-64.4$ |
| Net financial items | 2.3 | |||
| Pretax profit | $-62.1$ |
| 2022 Jan-Dec |
||||
|---|---|---|---|---|
| MSEK | Emcitate | Aladote | Common $\star$ |
Sum |
| Revenue | 21.9 | 0.6 | 22.6 | |
| Costs of sales of goods | $-6.3$ | $-6.3$ | ||
| Project costs | $-124.6$ | $-10.6$ | $-1.1$ | $-136.3$ |
| Other | $-78.0$ | $-78.0$ | ||
| Operating results | $-109.0$ | $-10.6$ | $-78.5$ | $-198.1$ |
| Net financial items | 4.3 | |||
| Pretax profit | $-193.8$ |
*) Revenue and project costs attributable to the parked PledOx project are provided in the "Common" column in the comparative period.
| 2023 | 2022 | 2023 | 2022 | 2022 | |
|---|---|---|---|---|---|
| KSEK | Apr-Jun | Apr-Jun | Jan-Jun | Jan-Jun | Jan-Dec |
| Re-invoicing of costs to | |||||
| Solasia | $\overline{\phantom{a}}$ | - | 0.5 | 0.6 | |
| Sales of goods | 5.9 | 4.7 | 12.7 | 11.2 | 21.9 |
| Total | 5.9 | 4.7 | 12.7 | 11.8 | 22.6 |
Egetis has a contractual obligation, on future net sales from Emcitate, to provide royalty payments to the previous owners of Rare Thyroid Therapeutics International AB and Erasmus Medical Center corresponding to a low double-digit percentage of net sales of the product.
Peder Walberg has been providing consultancy services to the company, invoicing MSEK 1,0 (0,6) during the period.
During the first half of 2023, the average share price exceeded the exercise price of the majority of the employee stock option plan (ESOP) 2022 why a dilution effect is reported in the number of shares after dilution. However, as earnings per share are negative, no dilution is reported in the key ratio earnings per share after dilution. As of June 30, 2023, the company has four ESOPs outstanding. Full utilization of the granted stock options would increase the number of shares in the company by 24,123,364. The total number of granted stock options have during the period increased with the granting of ESOP 2023.
The 2023 Annual General Meeting resolved on a 2023/2026 stock option plan of 9,000,000 stock options for employees at Egetis Therapeutics, of which 8,706,204 were granted to employees and key consultants, as of June 30, 2023. The CEO and the rest of the management team (eight individuals) were granted 1,313,869 and 4,653,285 employee stock options, respectively. To ensure the delivery of shares to participants in the incentive plans as
well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 10,350,000 warrants to its subsidiary Egetis Therapeutics Incentive AB.
The ESOP is implemented for employees and key consultants. The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to Egetis. Once the options are vested, they can be exercised within a six month period. Each vested option entitles the holder to acquire one share in Egetis at a predetermined price. The price per share is to be equivalent to 120% of the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the ten trading days preceding the allotment date, however, the price per share shall not be lower than SEK 7.2. The options have, at the time of issue, been valued according to the Black & Scholes valuation models. The exercise price is SEK 7.20 per option.
The 2022 Annual General Meeting resolved on a 2022/2026 stock option plan of 7,300,000 stock options for employees at Egetis Therapeutics, of which 7,300,000 were granted to employees and key consultants, as of March 31, 2023. The CEO and the rest of the management team (eight individuals) were granted 1,430,463 and 4,033,776 employee stock options, respectively. To ensure the delivery of shares to participants in the incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 9,592,200 warrants to its subsidiary Egetis Therapeutics Incentive AB.
The ESOP is implemented for employees and key consultants. The options were allotted free of charge to participants of the program. The options have a three-year vesting period calculated from the allotment date, provided that, with customary exceptions, the participants remain as employees of, or continue to provide services to Egetis. Once the options are vested, they can be exercised within a one-year period. Each vested option entitles the holder to acquire one share in Egetis at a predetermined price. The price per share is to be equivalent to 120% of the weighted average price that the company's shares were traded for on Nasdaq Stockholm during the ten trading days preceding the allotment date. The options have, at the time of issue, been valued according to the Black & Scholes valuation models. The exercise prices are in the interval of SEK 4.22-7.15 per option.
The 2021 Annual General Meeting resolved on a 2021/2025 stock option plan for employees at Egetis Therapeutics AB. The number of outstanding and granted stock options are 5,000,000. To ensure the delivery of shares to participants in the Company's incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued 6,571,000 warrants to its subsidiary Egetis Therapeutics Incentive AB. After re-calculation, according to the terms and conditions for the ESOP, for the May 2022 rights issue, every stock option is eligible to 1,02 shares and the updated exercise price is SEK 9.33 per option.
The 2020 Annual General Meeting resolved on a 2020/2024 stock option plan for employees at PledPharma (previous company name for Egetis Therapeutics AB). The number of granted stock options are 2,900,000. To ensure the delivery of shares to participants in the Company's incentive plans as well as to cover social security contributions when the share awards and employee options are exercised, the Parent Company has issued
3,942,600 warrants to its subsidiary Egetis Therapeutics Incentive AB. After re-calculation, according to the terms and conditions for the ESOP, for the November 2020 and May 2022 rights issues, the numbers of shares each stock option is entitled to is 1,0404 shares and the updated exercise price is SEK 11,71 per option.
Earnings per share. Net income divided by average number of shares before dilution.
Number of shares at end of period. The number of outstanding shares before dilution at the end of the period.
Number of shares after dilution. The number of issued shares after dilution effect of potential shares at end of period.
Average number of shares during the period. Average number of outstanding shares before dilution for the period.
Average number of shares during the period after dilution. Average number of issued shares after dilution effect of potential shares.
Project costs Refer to external costs that are directly attributable to the Group's costs regarding research and development of drug candidates.
Equity ratio, % The period's closing equity divided by the period's closing balance sheet. The Company uses the alternate Equity ratio as it shows the proportion of total assets represented by shareholders' equity and has been included to allow investors to assess the Company's capital structure.
Cash flow from operations per share. Cash flow from operating activities divided by the average number of shares outstanding at the end of the period. The Company uses the alternate key figure Cash flow from operations per share because the Company believes that the key ratio gives investors a better understanding of the Company's cash flow in relation to its number of shares adjusted for changes in the number of shares outstanding during the period.
Equity per share. Equity divided by number of shares outstanding at the end of the period. Outstanding stock options and warrants are only considered if they are "in the money". The Company uses the alternate key ratio equity per share because the Company believes that the key ratio gives investors a better understanding of the historical return per share adjusted for changes in the number of shares outstanding during the period.
Number of employees (average). The average number of employees at the end of each period.
| 2023 | 2022 | 2022 | ||
|---|---|---|---|---|
| Jan-Jun | Jan-Jun | Jan-De c | ||
| A | Equity, MSEK | 550.9 | 635.0 | 506.2 |
| B | Balance sheet total, MSEK | 608.8 | 661.1 | 561.1 |
| A/B | Equity ratio % | 90% | 96% | 90% |
| A | Net result, MSEK | $-154.2$ | $-62.1$ | $-193.8$ |
| B | Equity, MSEK | 550.9 | 635.0 | 506.2 |
| A/B | Return on equity, % | neg. | neg. | neg. |
| A | Cash flow from operating activities, MSEK | $-143.6$ | -68.4 | $-173.5$ |
| B | Average number of shares during the period, before dilution, thousand | 244.562 | 189.099 | 194.238 |
| A/B | Cash flow from operating activities per share, SEK | $-0.6$ | $-0.4$ | $-0.9$ |
| A | Equity, MSEK | 550.9 | 635.0 | 506.2 |
| B | Average number of shares at the end of the period before dilution, thousand | 244.562 | 189.099 | 194,238 |
| A/B | Equity per average number of shares before dilution, SEK | 2.3 | 3.4 | 2.6 |
| A | Equity, MSEK | 550.9 | 635.0 | 506.2 |
| B | Average number of shares at the end of the period after dilution, thousand | 249,612 | 189.099 | 194,238 |
| A/B | Equity per average number of shares after dilution, SEK | 2.3 | 3.4 | 2.6 |
*) The comparative figures in the table have been adjusted for the share issue in May 2022.
Interim report January 1- September 30: November 8, 2023. Full year results January 1- December 31: February 24, 2024.
This report, and further information is available on the website, www.egetis.com This report has not been reviewed by the Company's auditor. This is a translation of the Swedish interim report.
Nicklas Westerholm, CEO E-mail: [email protected] Yilmaz Mahshid, CFO E-mail: [email protected]
This information is such information as Egetis Therapeutics AB (publ) is obliged to disclose in accordance with EU market abuse regulation and the Securities Markets Act. The information was submitted, through the above contact persons, for publication on August 22, 2023, at 7.00 am (CEST).
Egetis Therapeutics AB (publ) Klara Norra kyrkogata 26, 111 22 Stockholm, Sweden Org.nr. 556706-6724 Phone: +46(0)8-679 72 10 www.egetis.com
ABGSC: Gonzalo Artiach Bryan, Garnier & Co: Alex Cogut Carnegie: Arvid Necander & Erik Hultgård Erik Penser Bank: Ludvig Svensson Pareto Securities: Chien-Hsun Lee & Dan Akschuti Redeye: Fredrik Thor Rx Securities: Joseph Hedden
This Half-Year report for January-June 2023 period provides a true and fair overview of the parent's and group's business activities, financial position, and results of operations, and describes significant risks and uncertainties to which the companies in the group are exposed.
Stockholm, August 22, 2023
| Thomas Lönngren | Mats Blom |
|---|---|
| Chairman of the board | Board member |
| Gunilla Osswald | Elisabeth Svanberg |
| Board member | Board member |
| Peder Walberg | Nicklas Westerholm |
| Board member | CEO |
Behshad Sheldon
Board member
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.